Last week, we reported on the completion of Comar’s move to a new building in West Bend, WI, under the headline: “Comar Triples Capacity in Fitting Finale to Year Marked by Growth.” It seems we jumped the gun with that headline — the supplier of custom medical devices and assemblies and specialty packaging wasn’t quite done growing for the year. It announced this week that it has acquired Omega Packaging, a manufacturer of injection- and blow-molded products serving the pharmaceutical, nutraceutical, sports nutrition, and skin-care markets. The terms of the transaction were not disclosed.
Comar said in the announcement that Omega Packaging's line of child-resistant (CR) closures and precision mold-building capabilities advance its strategy to serve healthcare customers with end-to-end custom manufacturing capabilities and an expanded product portfolio.
In operation for almost a decade, Omega primarily operates out of a Safe Quality Food (SQF) certified facility in La Mirada, CA, and ships products globally. Packaging products include CR and continuous thread (CT) closures and single, thick, and double-wall jars.
Comar’s customers will have access to a more expansive rigid packaging portfolio, increased CT and CR closures capacity, and an optimized production network. The combined company will have 11 manufacturing facilities and more than 1100 employees across the United States.
“Pairing Omega Packaging’s successful product portfolio with Comar’s geographically diverse network will enable us to serve our customers in the healthcare, personal care, and food and beverage markets in new and exciting ways,” said Scott Conklin, Executive Vice President of Sales and Marketing for Comar.
Comar CEO Mike Ruggieri added, “Omega Packaging has a distinct reputation for customer responsiveness and creative problem solving that aligns exceptionally well with Comar’s mission to bring transformative packaging and medical solutions to market. We look forward to a successful partnership and continuing on our journey of progress.”
The deal is backed by Morgan Stanley Capital Partners. Financing for the transaction was led by Golub Capital Credit Opportunities with participation from Brightwood Capital and Everberg Capital.